KR102538787B1 - Composition for enhancing awakening and concentration of human brain and uses thereof - Google Patents

Abstract

The present invention relates to an extract composition for increasing awakening and concentration, a health functional food for increasing awakening and concentration containing the composition, a method for producing an extract having an effect of increasing alertness and concentration, and an effect of increasing alertness and concentration prepared by the method Genie relates to baechohyang extract.

Description

Composition for enhancing awakening and concentration of human brain and uses thereof {Composition for enhancing awakening and concentration of human brain and uses thereof}

The present invention relates to an extract composition for increasing awakening and concentration, a health functional food for increasing awakening and concentration containing the composition, a method for producing an extract having an effect of increasing alertness and concentration, and an effect of increasing alertness and concentration prepared by the method It relates to a genie baechohyang extract, and the baechohyang extract composition of the present invention has AT (Absolute theta), AG (Absolute gamma), ALB (Absolute low beta), RB (Relative beta), RLB (Relative low beta) and Reduces SEF90 (Spectral edge frequency 90%), RSA (Relative slow alpha), RHB (Relative high beta), RSMT (Ratio of (SMR~mid beta) to theta), SEF50 (Spectral Edge Frequency 50%) and ASEF (Spectral edge frequency 50% of alpha) is induced to increase, which has the effect of strengthening awakening and concentration.

Baechohyang is a crop belonging to the Lamiaceae family and grows well throughout Northeast Asia and Korea, but is especially cultivated in the southern region. The stem is straight and square, the leaves are opposite, and the edge has round, blunt sawtooth. The front is almost hairless and the back is covered with short, soft hair. It grows on hillsides or around houses and roadsides. The flowering period is June-July, and the fruiting period is October-November.

Baechohyang is used as food or spice, but the aerial part of baechohyang has excellent effects on abdominal pain, diarrhea, vomiting and gastrointestinal diseases, and is also used as a medicine for cholera, antipyretic, and antibacterial action.

The main minerals of baechohyang are potassium, calcium, and sodium, and most of the components including magnesium were evaluated to be higher than other plants. The main components of free sugar were found to be fructose, glucose, sucrose, and maltose. The main constituent amino acids are glutamic acid, aspartic acid, and leucine.

In addition, it has been reported that monoterpene, sesquiterpene, diterpene, triterpene and flavonoids are contained, among which flavonoids include acacetin, It is known to contain tilianin, agastachin, agastachoside, isoagastachoside, and the like.

When the cerebral cortex is activated by a certain stimulus, brain waves are generated, which are electrical signals generated between neurons in the nervous system of the human cerebral cortex.

Electrodes that can amplify cerebral electrical activity are attached to the scalp, the obtained waveforms are recorded and analyzed as a graph, and EEG, an electrical signal generated by the autonomous activity of the brain, records and observes brain activity to improve human brain performance. It is used as an indicator of human psychophysiological functions such as arousal, activity, anxiety and stability. EEG is used in cognitive science, medicine, pharmacy, and criminal investigation because it has the advantage of being able to record and measure objectively, non-invasively, and continuously.

EEG mainly shows a frequency of 0 to 60 Hz and an amplitude of 5 to 300 V. Depending on the frequency range, delta waves (0 to 4 Hz), theta waves (4 to 8 Hz), alpha waves (8 to 13 Hz), beta waves It is divided into waves (13-30 Hz) and gamma waves (30-50 Hz). Delta waves and theta waves are slow waves and appear when thinking and working using information inside the brain. Beta waves higher than alpha waves are fast waves. In EEG analysis, relative power is used to reduce individual differences such as difference in thickness of the skull, electrical state of the scalp, and tension, as well as absolute power, and to analyze an accurate EEG response.

Korean Patent No. 0439182 discloses a composition for a beverage containing baechohyang extract, and Korean Patent No. 2059453 discloses a cosmetic composition for strengthening skin barrier and improving wrinkles containing a baechohyang leaf extract as an active ingredient, but the present invention It is different from the extract composition of baechohyang that improves the awakening and concentration of the brain.

The present invention has been derived from the above needs, and as a result of analyzing brain wave changes using the black pepper extract composition, the present inventors found that the black pepper extract composition of the present invention AT (Absolute theta), AG (Absolute gamma ), reduce absolute low beta (ALB), relative beta (RB), relative low beta (RLB) and spectral edge frequency 90% (SEF90), relative slow alpha (RSA), relative high beta (RHB), RSMT ( Ratio of (SMR~mid beta) to theta), SEF50 (Spectral Edge Frequency 50%) and ASEF (Spectral edge frequency 50% of alpha) were induced to increase, thereby confirming that there is an effect of enhancing arousal and concentration, thereby demonstrating the present invention. completed.

In order to solve the above problems, the present invention provides a baechohyang extract composition for increasing arousal and concentration containing the extract extracted after adding a solvent to baechohyang as an active ingredient.

In addition, the present invention provides a processed food for increasing alertness and concentration comprising the composition.

In addition, the present invention provides a pharmaceutical composition for improving wakefulness and concentration comprising the composition.

In addition, the present invention provides a method for producing an extract of baechohyang having an effect of increasing awakening and concentration, characterized in that it is prepared by adding a solvent to baechohyang and then extracting it.

In addition, the present invention provides a baechohyang extract having an effect of increasing arousal and concentration prepared by the above method.

The baechohyang extract composition of the present invention has AT (Absolute theta), AG (Absolute gamma), ALB (Absolute low beta), RB (Relative beta), RLB (Relative low beta) and SEF90 (Spectral edge frequency 90%), RSA (Relative slow alpha), RHB (Relative high beta), RSMT (Ratio of (SMR~mid beta) to theta), SEF50 (Spectral Edge Frequency 50%) and ASEF ( Spectral edge frequency (50% of alpha) is increased to improve brain arousal and attention, so various processed foods, functional health foods, pharmaceutical compositions, It can be used for the development of inner beauty products.

Figure 1 is a 3D brain map mapping results for changes in AT indicators before (left) and during (right) ingestion of Baechohyang extract.
Figure 2 is a 3D brain map mapping results for changes in AG indicators before ingestion (left side) and during ingestion (right side) of baechohyang extract.
Figure 3 is a 3D brain map mapping results for ALB index changes before (left) and during (right) ingestion of baechohyang extract.
Figure 4 is a 3D brain map mapping results for changes in RB indicators before (left) and during (right) ingestion of baechohyang extract.
Figure 5 is a 3D brain map mapping results for changes in RSA indicators before (left) and during (right) intake of baechohyang extract.
Figure 6 is a 3D brain map mapping results for RLB index changes before ingestion (left side) and during ingestion (right side) of baechohyang extract.
Figure 7 is a 3D brain map mapping results for changes in RHB indicators before (left) and during (right) ingestion of baechohyang extract.
8 is a 3D brain map mapping result for RSMT index changes before (left) and during (right) ingestion of Baechohyang extract.
9 is a 3D brain map mapping result for changes in the SEF50 index before (left) and during (right) intake of baechohyang extract.
10 is a 3D brain map mapping result for changes in the SEF90 index before ingestion (left side) and during ingestion (right side) of Baechohyang extract.
Figure 11 is a 3D brain map mapping results for ASEF index changes before (left) and during (right) ingestion of Baechohyang extract.

In order to achieve the object of the present invention, the present invention provides a baechohyang extract composition for increasing arousal and concentration containing the extract extracted after adding a solvent to baechohyang as an active ingredient.

The extract of the present invention may be preferably an extract extracted for 30 to 60 minutes at 50 to 100 ° C. after adding a solvent 5 to 10 times (w / w) to baechohyang, more preferably, a solvent to baechohyang 5 It may be an extract extracted for 30 to 60 minutes at 85 to 100 ° C. after adding ~ 10 times (w / w), but is not limited thereto.

The solvent may be water, C1-C4 lower alcohol, or a mixture thereof, more preferably water, but is not limited thereto.

The baechohyang extract composition of the present invention is AT (Absolute theta), AG (Absolute gamma), ALB (Absolute low beta), RB (Relative beta), RLB (Relative low beta) and SEF90 (Spectral edge frequency 90%) in specific brain regions ), RSA (Relative slow alpha), RHB (Relative high beta), RSMT (Ratio of (SMR~mid beta) to theta), SEF50 (Spectral Edge Frequency 50%) and ASEF (Spectral edge frequency 50% of alpha), and specifically, decreases AT (Absolute theta) in the left prefrontal lobe, right prefrontal lobe, left frontal lobe, central frontal lobe, left temporal lobe, left parietal lobe and left occipital lobe, and AG (Absolute gamma) in the right frontal lobe. ), decreased absolute low beta (ALB) in the left occipital lobe, decreased relative beta (RB) in the right occipital lobe, increased relative slow alpha (RSA) in the left occipital lobe and right occipital lobe, and RLB in the left occipital lobe (Relative low beta), increased RHB (Relative high beta) in the left prefrontal lobe, right prefrontal lobe and central frontal lobe, increased RSMT (Ratio of (SMR~mid beta) to theta) in the left frontal lobe, and right prefrontal lobe , increased SEF50 (Spectral Edge Frequency 50%) in the left prefrontal lobe, left frontal lobe, central frontal lobe and right temporal lobe, decreased SEF90 (Spectral edge frequency 90%) in the right temporal lobe and right parietal lobe, and ASEF (Spectral edge frequency 90%) in the right temporal lobe It is characterized by inducing an increase in frequency 50% of alpha) to show the effect of increasing arousal and concentration.

AT means the absolute power spectrum value of the theta wave region, and it is an indicator of light consciousness, and a decrease in AT means that light consciousness has a lower priority.

AG means the absolute power spectrum value of the gamma wave, and a decrease in AG means that anxiety or excitement due to high level of cognitive function is reduced.

ALB means the absolute power spectrum value of low beta waves, RB means the ratio of beta waves to the whole, RLB means the ratio of low beta waves to the whole, and the decrease of the ALB, RB, and RLB indicators It can be seen that concentration of attention is increased and expressed.

RHB means the ratio of High Beta waves in the whole, and High Beta waves appear when you concentrate on relatively complex reasoning or complex information processing activities with high mental load.

SEF90 means a frequency value corresponding to 90% of the area containing a specific frequency region of the brain wave, and its reduction means maintaining a level of mental load and stress that is not excessive.

RSA means the proportion of slow alpha waves in the whole, and an increase in RSA makes you mentally more orderly.

RSMT means SMR~Mid Beta wave/Theta wave, and is used as a neurophysiological brain wave concentration index.

SEF50 means a corresponding specific frequency value in which the area up to a specific frequency value occupies 50% of the area in the frequency domain, and an increase in SEF50 means an increase in brain arousal.

An increase in ASEF means an increase in the proportion of fast alpha waves in the entire brain wave. When the fast alpha wave increases, the brain is awakened and concentration is improved, and it becomes a state in which it can be maintained at a certain level.

The present invention also provides a processed food for increasing alertness and concentration comprising the composition of the present invention. The processed food of the present invention includes all forms such as functional food, nutritional supplement, health food and food additives. The above type of processed food can be prepared in various forms according to conventional methods known in the art.

For example, as a health food, the composition of the present invention may be prepared in the form of tea, juice, or drink to be consumed, or granulated, encapsulated, or powdered to be consumed. In addition, it may be prepared in the form of a composition by mixing the composition of the present invention with a known substance or active ingredient known to have an effect of enhancing alertness and concentration.

In addition, functional foods include beverages (including alcoholic beverages), fruits and their processed foods (e.g. canned fruit, bottled fruit, jam, marmalade, etc.), fish, meat and their processed foods (e.g. ham, sausage corned beef). etc.), breads and noodles (e.g. udon, buckwheat noodles, ramen, spaghetti, macaroni, etc.), fruit juice, various drinks, cookies, taffy, dairy products (e.g. butter, cheese, etc.), edible vegetable oil, margarine, vegetable protein , Retort foods, frozen foods, various seasonings (eg, soybean paste, soy sauce, sauce, etc.) can be prepared by adding the composition of the present invention.

In addition, in order to use the composition of the present invention in the form of a food additive, it can be prepared and used in the form of a powder or concentrate. A preferable content of the composition of the present invention may include about 1 to 100% by weight based on the total weight of food.

The health functional beverage composition of the present invention is not particularly limited in other components except for containing the composition as an essential component in the indicated ratio, and may contain various flavors or natural carbohydrates as additional components like conventional beverages. Examples of the aforementioned natural carbohydrates include monosaccharides such as glucose, fructose, and the like; disaccharides such as maltose, sucrose and the like; and polysaccharides such as conventional sugars such as dextrins, cyclodextrins, and the like, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (thaumatin, stevia extract, eg rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can advantageously be used. . The proportion of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 12 g per 100 ml of the composition of the present invention.

In addition to the above, the composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and enhancers (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its It may contain salts, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, and the like. In addition, the composition of the present invention may contain fruit flesh for preparing natural fruit juice, fruit juice beverages, and vegetable beverages. These components may be used independently or in combination. The proportion of these additives is not critical, but is generally selected from the range of 0 to about 20 parts by weight per 100 parts by weight of the composition of the present invention.

The present invention also provides a pharmaceutical composition for improving wakefulness and concentration comprising the composition of the present invention.

The pharmaceutical composition of the present invention can be prepared using a pharmaceutically suitable and physiologically acceptable adjuvant in addition to the above composition, and the adjuvant includes an excipient, a disintegrant, a sweetener, a binder, a coating agent, an expanding agent, a lubricant, a glidant or Flavoring agents etc. can be used.

The pharmaceutical composition may be preferably formulated as a pharmaceutical composition by including one or more pharmaceutically acceptable carriers in addition to the composition described above for administration.

Formulations of the pharmaceutical composition may be granules, powders, tablets, coated tablets, capsules, suppositories, solutions, syrups, juices, suspensions, emulsions, drops, or injectable solutions. For example, for formulation in the form of a tablet or capsule, the active ingredient may be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, or water.

In addition, if desired or necessary, suitable binders, lubricants, disintegrants and coloring agents may also be included in the mixture. Suitable binders include, but are not limited to, starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tracacanth or sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like. Disintegrants include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum, and the like.

In the composition formulated as a liquid solution, acceptable pharmaceutical carriers are sterile and biocompatible, and include saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol and these One or more of the components may be mixed and used, and other conventional additives such as antioxidants, buffers, and bacteriostatic agents may be added if necessary. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to prepare formulations for injections such as aqueous solutions, suspensions, and emulsions, pills, capsules, granules, or tablets.

The pharmaceutical composition of the present invention can be administered orally or parenterally, and in the case of parenteral administration, it can be administered by intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, transdermal administration, etc., preferably oral administration.

The suitable dosage of the pharmaceutical composition of the present invention varies depending on factors such as formulation method, administration method, patient's age, weight, sex, medical condition, food, administration time, administration route, excretion rate and reaction sensitivity, usually This allows the skilled physician to readily determine and prescribe dosages effective for the desired treatment or prophylaxis. According to a preferred embodiment of the present invention, the daily dose of the pharmaceutical composition of the present invention is 0.001-10 g/kg.

The pharmaceutical composition of the present invention is prepared in unit dosage form by formulation using pharmaceutically acceptable carriers and/or excipients according to a method that can be easily performed by those skilled in the art, or It can be prepared by placing it in a multi-dose container. In this case, the formulation may be in the form of a solution, suspension or emulsion in an oil or aqueous medium, or may be in the form of an extract, powder, granule, tablet or capsule, and may additionally contain a dispersing agent or stabilizer.

The present invention also

It is prepared by adding 5 to 10 times (w/w) of solvent to baechohyang and then extracting at 85 to 100 ° C for 30 to 60 minutes. Reduce AT (Absolute theta) in the occipital lobe, AG (Absolute gamma) in the right frontal lobe, ALB (Absolute low beta) in the left occipital lobe, RB (Relative beta) in the right occipital lobe, and left occipital lobe and decreased relative slow alpha (RSA) in the right occipital lobe, decreased relative low beta (RLB) in the left occipital lobe, increased relative high beta (RHB) in the left prefrontal lobe, right prefrontal lobe and central frontal lobe, and RSMT in the left frontal lobe. (Ratio of (SMR~mid beta) to theta), increased SEF50 (Spectral Edge Frequency 50%) in right prefrontal lobe, left prefrontal lobe, left frontal lobe, central frontal lobe and right temporal lobe, and increased SEF90 in right temporal lobe and right parietal lobe (Spectral edge frequency 90%) and ASEF (Spectral edge frequency 50% of alpha) is increased in the right temporal lobe.

The present invention also provides a baechohyang extract having an effect of increasing arousal and concentration prepared by the above method.

Hereinafter, the present invention will be described in detail by examples. However, the following examples are only to illustrate the present invention, and the content of the present invention is not limited to the following examples.

Example 1. Baechohyang extract

In this embodiment, at the lower end of the steam distillation extraction device (EssenLab-Plus, Hanil LabTech., Korea) connected to the cooling pipe in which -4 ° C cooling water is continuously flowing, distilled water and pear flavor are mixed at a weight ratio of 5 to 10: 1 The extract was extracted by maintaining the temperature of the steam generating part at 85 to 100 ° C. for 30 to 60 minutes. Then, moisture and impurities contained in the extract were removed using a small amount of anhydrous sodium sulfate (Dae Jung Chemicals & Metals Co. Ltd., Siheung-si, Korea). The finally obtained baechohyang extract was stored in a refrigerator maintained at 4 ° C., and then used in Example 2.

Example 2. Analysis of Organic Compounds Contained in Baechohyang Extract

Component analysis was performed by GC/MS (gas chromatography/mass spectrometry) in order to investigate the organic compounds constituting the baechohyang extract obtained through Example 1. The analytical instrument used in this example was Agilent's GC/MS (GC: 7890A, MS: 5975C), and the column used was HP-5MS (30 m × 0.32 mm × 0.25 μm, Agilent, USA). In GC analysis conditions, the direct (split mode) method was used for sample injection, and the inlet temperature at the time of sample injection was 250 °C. The GC oven conditions were maintained at 50 °C for 5 minutes, then increased by 5 °C per minute until reaching 250 °C and maintained at 250 °C for 3 minutes. Thereafter, the temperature was raised by 20 °C until reaching 300 °C and maintained for 5 minutes. As an analysis carrier gas, helium (He) flowed at a rate of 1 mL per minute. As for the MS analysis conditions, the ionization voltage was set to 70 eV and the ion source temperature was set to 280°C. Afterwards, the analyzed data was compared with the mass spectral data of the NIST library and the literature to identify the components of the extract.

Table 1 shows the organic compound results of the identified Baechohyang extract. There were a total of 30 organic compounds in the extract of Baechohyang identified by analysis in this Example, and the main components were estragole (92.35%), limonene (d-limonene, 1.81%), and caryophyllene (β-caryophyllene). , 1.84%), and β-cubebene (0.92%). Analyzing the results of this example, the extract of baechohyang produced in Example 1 contained the most estragol, so it can be classified as an estragol type as a chemical species.

Organic Compounds in Baechohyang Extract No. RT chemical name Area (%) Cas number chemical formula One 5.589 (Z)-3-Hexen-1-ol 0.01 928-96-1 C6H12O 2 10.048 1-Octen-3-ol 0.28 3391-86-4 C8H16O 3 10.230 3-Octanone 0.04 106-68-3 C8H16O 4 10.322 L-β-Pinene 0.01 18172-67-3 C10H16 5 11.716 D-Limonene 1.81 5989-27-5 C10H16 6 14.125 Linalool 0.01 78-70-6 C10H18O 7 14.360 1-Octen-3-yl-acetate 0.06 2442-10-06 C10H18O2 8 16.209 Menthone 0.02 89-80-5 C10H18O 9 16.542 Isopulegone 0.07 29606-79-9 C10H16O 10 17.416 Estragole 92.35 140-67-0 C10H12O 11 18.422 Pulegone 0.11 15932-80-6 C10H16O 12 19.324 (S)-Isopiperitenone 0.03 16750-82-6 C10H14O 13 19.801 Estragole 0.01 140-67-0 C10H12O 14 20.962 γ-Elemene 0.06 3242-08-08 C15H24 15 21.575 Eugenol 0.01 97-53-0 C10H12O2 16 21.998 2-Methoxy-3-(2-propenyl)-phenol 0.03 1941-12-04 C10H12O2 17 22.371 β-Bourbonene 0.02 5208-59-3 C15H24 18 22.504 (-)-β-Elemene 0.05 515-13-9 C15H24 19 22.833 Methyl eugenol 0.79 93-15-2 C11H14O2 20 23.320 β-Caryophyllene 1.84 87-44-5 C15H24 21 24.233 α-Humulene 0.06 6753-98-6 C15H24 22 24.870 β-Cubebene 0.92 13744-15-5 C15H24 23 25.235 γ-Elemene 0.74 3242-08-08 C15H24 24 25.354 Butylated hydroxytoluene 0.15 128-37-0 C15H24O 25 25.649 (R)-γ-Cadinene 0.01 39029-41-9 C15H24 26 25.758 β-Cadinene 0.05 523-47-7 C15H24 27 27.183 γ-Muurolene 0.35 30021-74-0 C15H24 28 28.691 T-Cadinol 0.01 5937-11-01 C15H26O 29 28.743 T-Muurolol 0.02 19912-62-0 C15H26O 30 29.001 T-Cadinol 0.04 5937-11-01 C15H26O Total 99.96

Example 3. Effect of Baechohyang Extract on Human EEG

Electroencephalogram (EEG) was measured to investigate the effect of the baechohyang extract obtained in Example 1 on human brain activity. In the present invention, brain wave measurement was conducted with 38 adult male and female participants in their 20s in an EEG measurement room of 32.4 m ² where appropriate temperature and humidity (temperature: 23 ℃, humidity: 50%) were maintained and noise was not mixed as much as possible. .

The EEG measuring device used for EEG measurement was the Quick-30 Dry EEG Headset (Cognionics, Inc. USA), Cognionics' Cognionics Data Acquisition Software was used to measure the participant's EEG signal, and LAXTHA's data collection equipment and analysis were used for EEG data analysis. A program (Telescan) was used.

First, the experiment participants were asked to wear an EEG cap with 29 ground electrodes distributed using the International 10-20 System, and before ingestion (non-stimulation) of Baechohyang extract from the air cylinder outlet located 5 cm in front of the experiment participant. It was adjusted to the intake state (stimulation) and measured for a total of 120 seconds (2 minutes) for 60 seconds each.

For 29 electrodes, EEG-only Drypad Sensors (Cognionics, Inc. USA) are used in the left and right prefrontal lobes (Fp1, Fp2), left and right frontal lobes (Af3, Af4, Fc5, Fc6, F3, Fz, F4, F7, F8), left and right temporal lobe (T7, T8, C3, Cz, C4, Cp5, Cp6), left and right parietal lobe (P3, Pz, P4, P7, P8), left and right occipital lobe (Po3, Po4, Po5, Po6, O1, O2) were attached using Flex Sensors (Cognionics, Inc. USA). Also, a reference electrode was attached to the left earlobe using Drypad Sensors.

EEG analysis extracts only representative EEG signals for 50 seconds from the EEG signals for each 60 seconds obtained before intake (non-stimulation) and intake status (stimulation) in the EEG measurement, and then uses an analysis program to perform the batch processing process. ) and 3D-mapping was performed. Afterwards, a paired-sample T-test was performed with SPSS (SPSS 24.0 version), a statistical analysis software program, to determine statistical significance between the pre-intake and ingestion status of Baechohyang extract ( p <0.05). The types of EEG indicators used for data analysis in this embodiment are shown in Table 2 below, and the meaning of each EEG indicator is shown in Table 3.

Types of EEG indicators used for data analysis No. Analysis indicator Full name of EEG analysis index Wavelength (Hz) One AT Absolute Theta Power Spectrum 4 to 8 2 AA Absolute Alpha Power Spectrum 8 to 13 3 AB Absolute Beta Power Spectrum 13 to 30 4 AG Absolute Gamma Power Spectrum 30 to 50 5 AFA Absolute Fast Alpha Power Spectrum 11~13 6 ASA Absolute Slow Alpha Power Spectrum 8-11 7 ALB Absolute Low Beta Power Spectrum 12 to 15 8 AMB Absolute Mid Beta Power Spectrum 15 to 20 9 AHB Absolute High Beta Power Spectrum 20 to 30 10 RT Relative Theta Power Spectrum (4~8)/(4~50) 11 RA Relative Alpha Power Spectrum (8~13)/(4~50) 12 RB Relative Beta Power Spectrum (13-30)/(4-50) 13 RG Relative Gamma Power Spectrum (30~50)/(4~50) 14 RFA Relative Fast Alpha Power Spectrum (11~13)/(4~50) 15 RSA Relative Slow Alpha Power Spectrum (8~11)/(4~50) 16 RLB Relative Low Beta Power Spectrum (12~15)/(4~50) 17 RMB Relative Mid Beta Power Spectrum (15~20)/(4~50) 18 RHB Relative High Beta Power Spectrum (20~30)/(4~50) 19 RST Ratio of SMR to Theta (12~15)/(4~8) 20 RMT Ratio of Mid Beta to Theta (15~20)/(4~8) 21 RSMT Ratio of (SMR-Mid Beta) to Theta (12~20)/(4~8) 22 RAHB Ratio of Alpha to High Beta (8~13)/(20~30) 23 SEF50 Spectral Edge Frequency 50% 4 to 50 24 SEF90 Spectral Edge Frequency 90% 4 to 50 25 ASEF Spectral Edge Frequency 50% of Alpha Spectrum Band 8 to 13

Meaning of EEG indicators used in EEG data analysis No. Analysis indicator meaning One AT Theta wave absolute power (light consciousness) 2 AA Alpha wave absolute power (relaxation, stability) 3 AB Absolute power of beta waves (tension, arousal, activation, cognitive function) 4 AG Absolute power of gamma waves (high level of cognitive action, excitement) 5 AFA Absolute power of fast alpha waves (immersion) 6 ASA Absolute power of slow alpha wave (relaxation) 7 ALB Absolute power of low beta wave, also called SMR wave (concentration, attention expression) 8 AMB Absolute power of mid beta waves (concentration, attention) 9 AHB Absolute power of high beta waves (stress, mental load, tension) 10 RT Percentage of theta waves in the total 11 RA Percentage of Alpha waves in the total 12 RB The ratio of beta waves to the total 13 RG Ratio of gamma waves to the total 14 RFA Percentage of Fast Alpha waves in total 15 RSA Percentage of Slow Alpha waves in the total 16 RLB Percentage of Low Beta waves in the total 17 RMB Percentage of Mid Beta waves in the total 18 RHB Percentage of High Beta waves in the total 19 RST Ratio of Theta waves in SMR waves in total 20 RMT Ratio of Mid Beta to Theta waves in total 21 RSMT SMR~Mid Beta wave/Theta wave (brain wave concentration index) 22 RAHB Alpha wave/High Beta wave (stabilization and relaxation) 23 SEF50 Median Frequency brain activity (brain wave arousal) 24 SEF90 Median Frequency brain activity (mental load, stress) 25 ASEF SEF50 of Alpha wave (comfort: there are many Fast Alpha waves)

As a result of analyzing the effect of the baechohyang extract obtained in Example 1 of the present invention on human brain waves, AT, AG, ALB, RB, RSA, RLB, RHB, RSMT, SEF50, SEF90, and ASEF indicators among a total of 25 brain wave indicators However, since it was found to be statistically significant ( p <0.05), only this will be explained.

When ingesting Baechohyang extract, RA (Cp5, Cp6, P8, P3, P4, Po5, Po6, Po3, Po4, O1, O2), RSA (Po3, O1, O2), RHB (Fp1, Fp2, Af4, Fz ), RSMT (F7), RAHB (P8, Po6, O1, O2), SEF50 (Fp2, Af3, F3, Fz, Cp6), ASEF (Cp6) increased, and AT (Fp1, Fp2, Af3, F7, F3, Fz, Fc5, T7, C3, Cp5, P3, P7, Po5, Po3, O1), AG(F8), ALB(Po5), RT(Af3, F7, Fz, C3, Cz, Cp5, Cp6, P7 , P3, Po5, Po3, Po4, O1, O2), RB (Po6, O2), RLB (Po5, Po3, O1), and SEF90 (T8, P8) indicators decreased.

Considering the present embodiment, it is determined that the baechohyang extract has a property of enhancing concentration and arousal of the human brain. Changes in each analysis index of EEG are explained below.

1. Changes in AT (Absolute theta) indicators

In this Example, as a result of measuring brain waves before and during intake of Baechohyang extract, left and right prefrontal lobes (Fp1, Fp2, Af3), left and central frontal lobes (F7, F3, Fz, Fc5), left temporal lobe (T7), electrode attachment sites , C3, Cp5), left parietal lobe (P7, P3), and left occipital lobe (Po5, Po3, O1), AT (Absolute theta) power spectrum was decreased statistically significantly ( p <0.05) (Table 4). The AT brain wave index is known as an indicator of light consciousness, and the 3D mapping change is shown in FIG. 1. This is interpreted as giving relatively shallow and light rituals less priority.

Changes in AT (Absolute theta) index before and during intake of Baechohyang extract AT (Absolute theta power spectrum) brain location situation number of subjects average Standard Deviation t-test Significance (p) Fp1 non-irritating 38 16.071 13.698 2.428 0.020 Stimulation 38 14.014 11.474 Fp2 non-irritating 38 18.459 14.207 2.116 0.041 Stimulation 38 16.477 13.358 Af3 non-irritating 38 17.304 13.665 3.105 0.004 Stimulation 38 15.502 12.132 F7 non-irritating 38 11.556 7.468 3.267 0.002 Stimulation 38 9.902 7.125 F3 non-irritating 38 17.589 12.825 2.735 0.010 Stimulation 38 16.424 11.760 Fz non-irritating 38 21.160 16.226 2.687 0.011 Stimulation 38 19.328 14.260 Fc5 non-irritating 38 11.551 7.763 3.072 0.004 Stimulation 38 10.477 7.476 T7 non-irritating 38 7.296 5.832 2.789 0.008 Stimulation 38 6.495 5.051 C3 non-irritating 38 14.259 9.798 3.032 0.004 Stimulation 38 13.207 9.649 Cp5 non-irritating 38 11.325 7.254 2.543 0.015 Stimulation 38 10.383 7.036 P7 non-irritating 38 9.158 5.993 2.996 0.005 Stimulation 38 8.221 6.304 P3 non-irritating 38 14.635 9.198 3.231 0.003 Stimulation 38 13.589 9.564 Po5 non-irritating 38 12.671 7.783 2.640 0.012 Stimulation 38 11.444 8.011 Po3 non-irritating 38 15.224 9.630 2.327 0.026 Stimulation 38 14.300 9.697 O1 non-irritating 38 12.706 7.474 2.856 0.007 Stimulation 38 11.289 7.177

Fp1/Af3: left prefrontal lobe, Fp2/Af4: right prefrontal lobe, F3/F7/Fc5: left frontal lobe, F4/F8/Fc6: right frontal lobe, Fz: central frontal lobe, T7/C3/Cp5: left temporal lobe, T8/C4/ Cp6: right temporal lobe, P3/P7: left parietal lobe, P4/P8: right parietal lobe, Cz/Pz: central parietal lobe, Po3/Po5/O1: left occipital lobe, Po4/Po6/O2: right occipital lobe

2. Changes in AG (Absolute gamma) index

As a result of measuring the EEG before and during intake of the baechohyang extract in this Example, the AG (Absolute gamma) power spectrum was statistically significantly ( p <0.05) reduced only in the right frontal lobe (F8) (Table 5). The AG brain wave index is known as an index that appears when high-level cognitive functions (attention, motivation, perception exchange, etc.) are performed, and a decrease in AG index means that anxiety or excitement due to high-level cognitive functions is reduced. Intake can remove anxiety factors and maintain a high level of cognitive function. 3D mapping of AG indicators is shown in FIG. 2 .

Changes in AG (Absolute gamma) index before and during ingestion of Baechohyang extract AG (Absolute gamma power spectrum) brain location situation number of subjects average Standard Deviation t-test Significance (p) F8 non-irritating 38 4.840 2.280 2.074 0.045 Stimulation 38 4.570 2.020

Fp1/Af3: left prefrontal lobe, Fp2/Af4: right prefrontal lobe, F3/F7/Fc5: left frontal lobe, F4/F8/Fc6: right frontal lobe, Fz: central frontal lobe, T7/C3/Cp5: left temporal lobe, T8/C4/ Cp6: right temporal lobe, P3/P7: left parietal lobe, P4/P8: right parietal lobe, Cz/Pz: central parietal lobe, Po3/Po5/O1: left occipital lobe, Po4/Po6/O2: right occipital lobe

3. Changes in ALB (Absolute Low Beta) Indicators

In this Example, as a result of measuring the EEG before and after ingestion of the baechohyang extract, the ALB (Absolute low beta) power spectrum was reduced statistically significantly ( p <0.05) only in the left occipital lobe (Po5) (Table 6, FIG. 3 ).

Changes in ALB (Absolute low beta) index before and during intake of Baechohyang extract ALB (Absolute low beta power spectrum) brain location situation number of subjects average Standard Deviation t-test Significance (p) Po5 non-irritating 38 8.5204 7.4283 2.118 0.041 Stimulation 38 7.5712 6.8700

Fp1/Af3: left prefrontal lobe, Fp2/Af4: right prefrontal lobe, F3/F7/Fc5: left frontal lobe, F4/F8/Fc6: right frontal lobe, Fz: central frontal lobe, T7/C3/Cp5: left temporal lobe, T8/C4/ Cp6: right temporal lobe, P3/P7: left parietal lobe, P4/P8: right parietal lobe, Cz/Pz: central parietal lobe, Po3/Po5/O1: left occipital lobe, Po4/Po6/O2: right occipital lobe

4. Changes in relative beta (RB) indicators

In this Example, as a result of measuring the EEG before and after ingestion of the baechohyang extract, the RB (Relative beta) power spectrum decreased statistically significantly ( p <0.05) only in the electrode attachment site, the right occipital lobe (Po6, O2) ( Table 7, Figure 4). The RB EEG index represents the relative value of beta waves (13 to 30 Hz) among the entire brain waves.

Changes in RB (Relative Beta) Indicators Before and During Ingestion of Baechohyang Extract Relative beta power spectrum (RB) brain location situation number of subjects average Standard Deviation t-test Significance (p) Po6 non-irritating 38 0.2140 0.0814 2.273 0.029 Stimulation 38 0.2001 0.0836 O2 non-irritating 38 0.2177 0.0772 2.110 0.042 Stimulation 38 0.2046 0.0783

Fp1/Af3: left prefrontal lobe, Fp2/Af4: right prefrontal lobe, F3/F7/Fc5: left frontal lobe, F4/F8/Fc6: right frontal lobe, Fz: central frontal lobe, T7/C3/Cp5: left temporal lobe, T8/C4/ Cp6: right temporal lobe, P3/P7: left parietal lobe, P4/P8: right parietal lobe, Cz/Pz: central parietal lobe, Po3/Po5/O1: left occipital lobe, Po4/Po6/O2: right occipital lobe

5. Changes in relative slow alpha (RSA) indicators

In this Example, as a result of measuring the EEG before and after ingestion of the baechohyang extract, the RSA (Relative slow alpha) power spectrum was statistically significant ( p <0.05) only in the left and right occipital lobes (Po3, O1, O2), which are electrode attachment sites. increased (Table 8, Figure 5). The RSA EEG index is the relative value of slow alpha waves (8 to 11 Hz) among the entire brain waves, and slow alpha waves are known as brain waves that occur when the person is in a more mentally organized state.

Changes in RSA (Relative slow alpha) index before and during intake of Baechohyang extract RSA (Relative slow alpha power spectrum) brain location situation number of subjects average Standard Deviation t-test Significance (p) Po3 non-irritating 38 0.3279 0.1730 -2.185 0.035 Stimulation 38 0.3560 0.1739 O1 non-irritating 38 0.3490 0.1862 -2.099 0.043 Stimulation 38 0.3745 0.1922 O2 non-irritating 38 0.3434 0.1904 -2.050 0.047 Stimulation 38 0.3696 0.1826

Fp1/Af3: left prefrontal lobe, Fp2/Af4: right prefrontal lobe, F3/F7/Fc5: left frontal lobe, F4/F8/Fc6: right frontal lobe, Fz: central frontal lobe, T7/C3/Cp5: left temporal lobe, T8/C4/ Cp6: right temporal lobe, P3/P7: left parietal lobe, P4/P8: right parietal lobe, Cz/Pz: central parietal lobe, Po3/Po5/O1: left occipital lobe, Po4/Po6/O2: right occipital lobe

6. Changes in relative low beta (RLB) indicators

In this Example, as a result of measuring the EEG before and after ingestion of the baechohyang extract, the RLB (Relative low beta) power spectrum decreased statistically significantly ( p <0.05) only in the left occipital lobe (Po5, Po3, O1) (Table 9, Fig. 6). The RLB EEG index is a relative value of low beta waves (13 to 15 Hz) among the entire brain waves, and low beta waves are also called SMR waves.

Changes in RLB (Relative low beta) index before and during ingestion of Baechohyang extract Relative low beta power spectrum (RLB) brain location situation number of subjects average Standard Deviation t-test Significance (p) Po5 non-irritating 38 0.1028 0.0723 2.244 0.031 Stimulation 38 0.0915 0.0660 Po3 non-irritating 38 0.1206 0.0848 2.139 0.039 Stimulation 38 0.1072 0.0739 O1 non-irritating 38 0.1071 0.0728 2.051 0.047 Stimulation 38 0.0969 0.0679

Fp1/Af3: left prefrontal lobe, Fp2/Af4: right prefrontal lobe, F3/F7/Fc5: left frontal lobe, F4/F8/Fc6: right frontal lobe, Fz: central frontal lobe, T7/C3/Cp5: left temporal lobe, T8/C4/ Cp6: right temporal lobe, P3/P7: left parietal lobe, P4/P8: right parietal lobe, Cz/Pz: central parietal lobe, Po3/Po5/O1: left occipital lobe, Po4/Po6/O2: right occipital lobe

7. Changes in relative high beta (RHB) indicators

In this Example, as a result of measuring the EEG before and during the intake of the baechohyang extract, the relative high beta (RHB) power spectrum was statistically significant in the left and right prefrontal lobes (Fp1, Fp2, Af4) and the central frontal lobe (Fz) ( p < 0.05) increased (Table 10, Figure 7). The RHB EEG index is a relative value of high beta waves (20 to 30 Hz) among the entire brain waves, and high beta waves are known to be relatively high when in a state of strong concentration.

Changes in RHB (Relative high beta) index before and during intake of Baechohyang extract Relative high beta power spectrum (RHB) brain location situation number of subjects average Standard Deviation t-test Significance (p) Fp1 non-irritating 38 0.1010 0.0498 -2.274 0.029 Stimulation 38 0.1098 0.0560 Fp2 non-irritating 38 0.0993 0.0479 -2.333 0.025 Stimulation 38 0.1061 0.0536 Af4 non-irritating 38 0.0932 0.0483 -2.210 0.033 Stimulation 38 0.0986 0.0508 Fz non-irritating 38 0.0898 0.0502 -2.199 0.034 Stimulation 38 0.0945 0.0489

Fp1/Af3: left prefrontal lobe, Fp2/Af4: right prefrontal lobe, F3/F7/Fc5: left frontal lobe, F4/F8/Fc6: right frontal lobe, Fz: central frontal lobe, T7/C3/Cp5: left temporal lobe, T8/C4/ Cp6: right temporal lobe, P3/P7: left parietal lobe, P4/P8: right parietal lobe, Cz/Pz: central parietal lobe, Po3/Po5/O1: left occipital lobe, Po4/Po6/O2: right occipital lobe

8. Changes in RSMT (Ratio of (SMR~mid beta) to theta) index

In this Example, as a result of measuring the EEG before and after ingestion of the baechohyang extract, the RSMT (Ratio of (SMR ~ mid beta) to theta) power spectrum increased statistically significantly ( p <0.05) only in the left frontal lobe (F7). (Table 11, Figure 8). The RSMT EEG index is the ratio of SMR-mid beta (12-20 Hz) / theta (4-8 Hz) in the EEG spectrum, which means the spectrum value obtained by dividing the SMR-mid beta wave area by the theta wave area. This is known as a neurophysiological EEG concentration index that can objectively confirm the state of concentration.

Changes in RSMT (Ratio of (SMR~mid beta) to theta) index before and during ingestion of Baechohyang extract RSMT (Ratio of (SMR~mid beta) to theta power spectrum) brain location situation number of subjects average Standard Deviation t-test Significance (p) F7 non-irritating 38 0.5728 0.3237 -2.280 0.028 Stimulation 38 0.6383 0.3036

Fp1/Af3: left prefrontal lobe, Fp2/Af4: right prefrontal lobe, F3/F7/Fc5: left frontal lobe, F4/F8/Fc6: right frontal lobe, Fz: central frontal lobe, T7/C3/Cp5: left temporal lobe, T8/C4/ Cp6: right temporal lobe, P3/P7: left parietal lobe, P4/P8: right parietal lobe, Cz/Pz: central parietal lobe, Po3/Po5/O1: left occipital lobe, Po4/Po6/O2: right occipital lobe

9. Changes in SEF50 (Spectral edge frequency 50%) index

In this Example, as a result of measuring the brain waves before and after ingestion of the baechohyang extract, SEF50 (Spectral edge frequency 50%) in the left and right prefrontal lobes (Fp2, Af3), left and central frontal lobes (F3, Fz) and right temporal lobe (Cp6) The power spectrum increased statistically significantly ( p <0.05) (Table 12, FIG. 9). The SEF index is a method of quantifying how much the brainwave power spectrum distribution is biased towards high frequencies compared to low frequencies in terms of frequency. A higher SEF value means that a relatively high frequency component appears in the power spectrum distribution. The SEF50 EEG index means a frequency value corresponding to 50% of an area including a specific frequency region of an EEG, and is known as an index indicating brain arousal.

Changes in SEF50 (Spectral Edge Frequency 50%) index before and during ingestion of Baechohyang extract SEF50 (Spectral edge frequency 50% power spectrum) brain location situation number of subjects average Standard Deviation t-test Significance (p) Fp2 non-irritating 38 10.5205 2.3757 -2.333 0.025 Stimulation 38 10.9759 2.7401 Af3 non-irritating 38 10.0764 1.1088 -2.833 0.007 Stimulation 38 10.3615 1.1904 F3 non-irritating 38 10.1415 1.0139 -2.406 0.021 Stimulation 38 10.3286 1.1031 Fz non-irritating 38 9.9351 0.9956 -2.457 0.019 Stimulation 38 10.1712 1.0295 Cp6 non-irritating 38 10.7470 1.6781 -2.234 0.032 Stimulation 38 11.0634 1.8708

Fp1/Af3: left prefrontal lobe, Fp2/Af4: right prefrontal lobe, F3/F7/Fc5: left frontal lobe, F4/F8/Fc6: right frontal lobe, Fz: central frontal lobe, T7/C3/Cp5: left temporal lobe, T8/C4/ Cp6: right temporal lobe, P3/P7: left parietal lobe, P4/P8: right parietal lobe, Cz/Pz: central parietal lobe, Po3/Po5/O1: left occipital lobe, Po4/Po6/O2: right occipital lobe

10. Changes in SEF90 (Spectral edge frequency 90%) index

In this Example, as a result of measuring the EEG before and after ingestion of the baechohyang extract, the SEF90 (Spectral edge frequency 90%) power spectrum in the right temporal lobe (T8) and right parietal lobe (P8) was statistically significant ( p <0.05) decreased (Table 13, Figure 10). The SEF90 EEG index means a frequency value for which the area containing a specific frequency region of the brain wave corresponds to 90%. Indicates arousal and stress levels.

Changes in SEF90 (Spectral edge frequency 90%) power spectrum before and during ingestion of Baechohyang extract SEF50 (Spectral edge frequency 50% power spectrum) brain location situation number of subjects average Standard Deviation t-test Significance (p) T8 non-irritating 38 30.7898 7.6941 2.305 0.027 Stimulation 38 29.8831 7.3417 P8 non-irritating 38 26.2588 6.9865 2.270 0.029 Stimulation 38 25.2918 7.2532

Fp1/Af3: left prefrontal lobe, Fp2/Af4: right prefrontal lobe, F3/F7/Fc5: left frontal lobe, F4/F8/Fc6: right frontal lobe, Fz: central frontal lobe, T7/C3/Cp5: left temporal lobe, T8/C4/ Cp6: right temporal lobe, P3/P7: left parietal lobe, P4/P8: right parietal lobe, Cz/Pz: central parietal lobe, Po3/Po5/O1: left occipital lobe, Po4/Po6/O2: right occipital lobe

11. Changes in ASEF (Spectral edge frequency 50% of alpha) index

In this Example, as a result of measuring the EEG before and after ingestion of the baechohyang extract, the ASEF (Spectral edge frequency 50% of alpha) power spectrum increased statistically significantly ( p <0.05) only in the right temporal lobe (Cp6) (Table 14, Fig. 11). The ASEF EEG index means the SEF50 value of the alpha wave power spectrum and represents the activity of the alpha wave. This indicates that brain stability was increased by ingestion of Baechohyang extract.

Changes in ASEF (Spectral edge frequency 50% of alpha) index before and during intake of Baechohyang extract Spectral edge frequency 50% of alpha power spectrum (ASEF) brain location situation number of subjects average Standard Deviation t-test Significance (p) Cp6 non-irritating 38 10.3760 0.6298 -2.178 0.036 aroma stimulation 38 10.4916 0.5527

Fp1/Af3: left prefrontal lobe, Fp2/Af4: right prefrontal lobe, F3/F7/Fc5: left frontal lobe, F4/F8/Fc6: right frontal lobe, Fz: central frontal lobe, T7/C3/Cp5: left temporal lobe, T8/C4/ Cp6: right temporal lobe, P3/P7: left parietal lobe, P4/P8: right parietal lobe, Cz/Pz: central parietal lobe, Po3/Po5/O1: left occipital lobe, Po4/Po6/O2: right occipital lobe

As a result of this example, the increase in RHB index in the prefrontal lobe and the frontal lobe and the increase in the RSMT index in the frontal lobe increased concentration, increased SEF50 index in the prefrontal lobe and frontal lobe, increased arousal, and decreased SEF90 index in the temporal lobe and parietal lobe, resulting in excessive stress showed a decrease in

Taken together, it is evaluated that the extract of Baechohyang, in which estragol is the main chemical species, induced high-level cognitive function, stable concentration improvement, and arousal in all parts of the human brain.

Claims (8)

At the bottom of the steam distillation extraction device connected to the cooling pipe, where cooling water is continuously flowing, water and pear grass are added in a weight ratio of 5 to 10:1, and the temperature of the steam generating part is maintained at 85 to 100 ℃ for 30 to 60 minutes. Extraction doing; and
As an extract composition for increasing concentration, containing, as an active ingredient, the extract of the extract prepared by removing moisture and impurities contained in the extract using anhydrous sodium sulfate,
The baechohyang extract is (Z) -3-hexen-1-ol ((Z) -3-Hexen-1-ol), 1-octen-3-ol (1-Octen-3-ol), 3-octanone (3-Octanone), L-β-Pinene, D-Limonene, Linalool, 1-octen-3-yl-acetate (1-Octen-3- yl-acetate), Menthone, Isopulegone, Estragole, Pulegone, (S)-Isopiperitenone, γ-element ( γ-Elemene), Eugenol, 2-Methoxy-3-(2-propenyl)-phenol, β-Bourbonene ), (-)-β-Elemene, Methyl eugenol, β-Caryophyllene, α-Humulene, β -Cubeben (β-Cubebene), butylated hydroxytoluene (Butylated hydroxytoluene), (R)-γ-cadinene ((R)-γ-Cadinene, β-cadinene (β-Cadinene), γ- It contains an organic compound composed of γ-Muurolene, T-Muurolol and T-Cadinol,
The baechohyang extract reduces AT (Absolute theta) in the left frontal lobe, right frontal lobe, left frontal lobe, central frontal lobe, left temporal lobe, left parietal lobe and left occipital lobe, reduces AG (Absolute gamma) in the right frontal lobe, and ALB in the left occipital lobe (absolute low beta), decrease RB (relative beta) in the right occipital lobe, increase RSA (relative slow alpha) in the left occipital lobe and right occipital lobe, reduce RLB (relative low beta) in the left occipital lobe, Relative high beta (RHB) was increased in the left prefrontal lobe, right prefrontal lobe and central frontal lobe, RSMT (Ratio of (SMR~mid beta) to theta) was increased in the left frontal lobe, right prefrontal lobe, left prefrontal lobe, left frontal lobe, and central frontal lobe And increasing SEF50 (Spectral Edge Frequency 50%) in the right temporal lobe, reducing SEF90 (Spectral edge frequency 90%) in the right temporal lobe and right parietal lobe, and increasing ASEF (Spectral edge frequency 50% of alpha) in the right temporal lobe Baechohyang extract composition for increasing concentration, characterized in that. According to claim 1, wherein the black pepper extract extract composition for increasing concentration characterized in that it has a wakefulness increasing effect additionally. delete delete delete delete delete delete

Images